KLRA Kailera Therapeutics, Inc.

NASDAQ
$17.75

Kailera Therapeutics, Inc. (KLRA) Institutional Ownership

What the institutions did with KLRA last quarter, from their 13F filings. Counting managers rather than shares is the point: a single index fund adding to a position tells you far less than four hundred separate managers all deciding to. Positions as reported for the quarter ended June 30, 2026.

Managers reporting
98
filed a 13F this quarter
Managers holding
98
+98 on the quarter
Buyers
98
98 opened new
Sellers
0
0 sold out entirely
Buyer share
100.0%
of managers who traded it
Breadth
+100.0
net buyers, as a share of those trading

Every manager below opens. Subscribers can see any firm's whole portfolio — every position, its weight, and what they bought, trimmed and exited last quarter.

Sign in or subscribe

Largest holders

Manager Shares % of reported
Bain Capital Investors LLC 26.3M 22.6%
Bain Capital Life Sciences Investors, LLC 22.6M 19.4%
RTW INVESTMENTS, LP 10.8M 9.3%
CANADA PENSION PLAN INVESTMENT BOARD 7.3M 6.3%
Atlas Venture Life Science Advisors, LLC 5.2M 4.5%
FMR LLC 4.0M 3.4%
BlackRock, Inc. 3.9M 3.4%
PRICE T ROWE ASSOCIATES INC /MD/ 3.5M 3.0%
CITADEL ADVISORS LLC 3.2M 2.8%
ADAGE CAPITAL PARTNERS GP, L.L.C. 3.2M 2.8%
WELLINGTON MANAGEMENT GROUP LLP 2.9M 2.5%
Royalty Pharma Sub-Manager, LLC 2.5M 2.1%
Siren, L.L.C. 2.2M 1.9%
VANGUARD CAPITAL MANAGEMENT LLC 1.7M 1.5%
VANGUARD PORTFOLIO MANAGEMENT LLC 1.7M 1.4%
GEODE CAPITAL MANAGEMENT, LLC 1.1M 1.0%
FARALLON CAPITAL MANAGEMENT LLC 1.1M 0.9%
Frazier Life Sciences Management, L.P. 1.1M 0.9%
Trails Edge Capital Partners, LP 984.8K 0.8%
UBS Group AG 972.7K 0.8%
Jupiter Topco LLC 970.9K 0.8%
AMERIPRISE FINANCIAL INC 821.3K 0.7%
Deep Track Capital, LP 700.0K 0.6%
EVENTIDE ASSET MANAGEMENT, LLC 616.7K 0.5%
Vestal Point Capital, LP 575.0K 0.5%

Largest changes

Manager Action Previous Current Change
Bain Capital Investors LLC New 0 26.3M +26.3M
Bain Capital Life Sciences Investors, LLC New 0 22.6M +22.6M
RTW INVESTMENTS, LP New 0 10.8M +10.8M
CANADA PENSION PLAN INVESTMENT BOARD New 0 7.3M +7.3M
Atlas Venture Life Science Advisors, LLC New 0 5.2M +5.2M
FMR LLC New 0 4.0M +4.0M
BlackRock, Inc. New 0 3.9M +3.9M
PRICE T ROWE ASSOCIATES INC /MD/ New 0 3.5M +3.5M
CITADEL ADVISORS LLC New 0 3.2M +3.2M
ADAGE CAPITAL PARTNERS GP, L.L.C. New 0 3.2M +3.2M
WELLINGTON MANAGEMENT GROUP LLP New 0 2.9M +2.9M
Royalty Pharma Sub-Manager, LLC New 0 2.5M +2.5M
Siren, L.L.C. New 0 2.2M +2.2M
VANGUARD CAPITAL MANAGEMENT LLC New 0 1.7M +1.7M
VANGUARD PORTFOLIO MANAGEMENT LLC New 0 1.7M +1.7M
GEODE CAPITAL MANAGEMENT, LLC New 0 1.1M +1.1M
FARALLON CAPITAL MANAGEMENT LLC New 0 1.1M +1.1M
Frazier Life Sciences Management, L.P. New 0 1.1M +1.1M
Trails Edge Capital Partners, LP New 0 984.8K +984.8K
UBS Group AG New 0 972.7K +972.7K
AMERIPRISE FINANCIAL INC New 0 821.3K +821.3K
Deep Track Capital, LP New 0 700.0K +700.0K
EVENTIDE ASSET MANAGEMENT, LLC New 0 616.7K +616.7K
Vestal Point Capital, LP New 0 575.0K +575.0K
Cormorant Asset Management, LP New 0 550.0K +550.0K

13F filings are due 45 days after quarter end and cover long positions in U.S.-listed equities only, so this is a lagged and partial picture: shorts, bonds and foreign listings never appear. Options positions are excluded here rather than folded into the share counts. Political ownership is coming.